{"title":"难治性溃疡性结肠炎：乌达帕替尼与其他生物制剂的比较。","authors":"Said G Farhat, Jessy G Fadel","doi":"10.12998/wjcc.v12.i31.6425","DOIUrl":null,"url":null,"abstract":"<p><p>In this editorial we comment on an article published in <i>World Journal of Clinical Cases</i> in 2024, in which a case of refractory ulcerative colitis (UC) was discussed based on the response to different lines of biologics. Different studies showed that different classes of biologics have their advantages and disadvantages in the treatment of refractory UC. Certain classes are superior to others and if tried earlier on would lead to a possible change in the outcome.</p>","PeriodicalId":23912,"journal":{"name":"World Journal of Clinical Cases","volume":"12 31","pages":"6425-6427"},"PeriodicalIF":1.0000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438697/pdf/","citationCount":"0","resultStr":"{\"title\":\"Refractory ulcerative colitis: Upadacitinib versus other biologics.\",\"authors\":\"Said G Farhat, Jessy G Fadel\",\"doi\":\"10.12998/wjcc.v12.i31.6425\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this editorial we comment on an article published in <i>World Journal of Clinical Cases</i> in 2024, in which a case of refractory ulcerative colitis (UC) was discussed based on the response to different lines of biologics. Different studies showed that different classes of biologics have their advantages and disadvantages in the treatment of refractory UC. Certain classes are superior to others and if tried earlier on would lead to a possible change in the outcome.</p>\",\"PeriodicalId\":23912,\"journal\":{\"name\":\"World Journal of Clinical Cases\",\"volume\":\"12 31\",\"pages\":\"6425-6427\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438697/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Clinical Cases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12998/wjcc.v12.i31.6425\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Clinical Cases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12998/wjcc.v12.i31.6425","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
在这篇社论中，我们对 2024 年发表在《世界临床病例杂志》（World Journal of Clinical Cases）上的一篇文章进行了评论，这篇文章根据对不同系列生物制剂的反应讨论了一个难治性溃疡性结肠炎（UC）病例。不同的研究表明，不同类别的生物制剂在治疗难治性溃疡性结肠炎方面各有利弊。某些类别的生物制剂优于其他类别的生物制剂，如果尽早试用，可能会改变治疗结果。
Refractory ulcerative colitis: Upadacitinib versus other biologics.
In this editorial we comment on an article published in World Journal of Clinical Cases in 2024, in which a case of refractory ulcerative colitis (UC) was discussed based on the response to different lines of biologics. Different studies showed that different classes of biologics have their advantages and disadvantages in the treatment of refractory UC. Certain classes are superior to others and if tried earlier on would lead to a possible change in the outcome.
期刊介绍：
The World Journal of Clinical Cases (WJCC) is a high-quality, peer reviewed, open-access journal. The primary task of WJCC is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of clinical cases. In order to promote productive academic communication, the peer review process for the WJCC is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCC are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in clinical cases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
